Materials and methods for treating hypercholesterolemia
The subject invention provides novel HMG-CoA-reductase inhibitors. In a preferred embodiment, the HMG-CoA reductase inhibitors of the subject invention can be deactivated to a primary inactive metabolite by hydrolytic enzymes. Compounds of the present invention can be advantageously used to treat patients suffering hypercholesterolemia.
1. Compounds having the following structure:
or pharmaceutically acceptable salts thereof,
where n is 0, 1, 2, or 3; and
where R is
2. Compounds having the following structure:
or pharmaceutically acceptable salts thereof,
where n is 1, 2, or 3; and
where R is
3. Inhibitors of HMG-CoA reductase having the following structure:
or pharmaceutically acceptable salts thereof,
where n is 1, 2, or 3; and
where R is
4. Inhibitors of HMG-CoA reductase having the following structures:
or pharmaceutically acceptable salts thereof,
where
n is 0, 1, 2, or 3; and
where R is
5. A pharmaceutical composition comprising at least one compound or pharmaceutically acceptable salt of claim 1 and a pharmaceutically acceptable solvent, carrier, excipient or combinations thereof.
6. A pharmaceutical composition comprising at least one compound or pharmaceutically acceptable salt of claim 2 and a pharmaceutically acceptable solvent, carrier, excipient or combinations thereof.